Cancer
Cancer Ongoing 2020 North Florida / Jacksonville: Astrid Corrales-Cruz (904) 427-1217

TG Therapeutics 304

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic

Trial overview

Disease
Blood cancer treatment and diagnosis – TBC
Topic
TG Therapeutics 304
Description
This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL).
Physicians

Dr. Troy H. Guthrie, Jr.

MD

Medical Oncologist

Works at 2 centers.